#United States #Boston #Cell Therapy #PBS Biotech #MiniPRO

PBS Biotech Unveils MiniPRO™ for Cell Therapy Development

PBS Biotech, a prominent figure in the realm of single-use bioreactor technology, recently launched the MiniPRO™, a cutting-edge multi-parallel Vertical-Wheel® bioreactor platform. This game-changing product was announced ahead of its showcase at the ISSCR PSC-Derived Therapies Symposium in Boston this December. The MiniPRO™ is tailored for high-throughput cell therapy process development, providing researchers with the ability to run up to 24 independent cultures simultaneously.

Advanced Features of the MiniPRO™

The MiniPRO™ stands out with its automated closed system that is equipped to control and monitor essential parameters such as temperature, agitation, oxygenation, and pH in real time. Additionally, it features perfusion media exchange, enabling a comprehensive set of functionalities that streamline the early stages of process development. As a result, researchers can efficiently optimize and scale their manufacturing processes—an essential requirement in the fast-evolving field of cell therapy.

CTO and founder Brian Lee emphasized the increasing demand from companies for an automated small-scale system that accurately mimics clinical manufacturing equipment performance. The MiniPRO™ fills this gap by offering precise control and real-time monitoring in a closed environment, which is critical for more consistent and speedy process development.

The Technology Behind MiniPRO™

Built on PBS Biotech's patented Vertical-Wheel® technology, the MiniPRO™ mirrors the performance characteristics of larger GMP-ready bioreactors. With this innovative design, researchers can replicate fluid dynamics at a miniature scale, ensuring that the processes developed in the lab can be effectively transferred and scaled with enhanced confidence.

This unique approach aligns with the broader trend in the cell therapy market, which is progressively moving towards standardized and scalable manufacturing practices. As CEO Martin Simonetti noted, the positive responses from customers and industry partners have been overwhelmingly strong. The MiniPRO™ addresses a crucial need—serving as a bridge between research and clinical production.

Attending the ISSCR Symposium

Attendees at the ISSCR Symposium will have the opportunity to engage with the MiniPRO™ during an Innovation Showcase, led by Sharon Harvey, PBS Biotech's Director of Product Management Strategy. This interactive session will provide insights into the technology and its potential impact on cell therapy process development.

PBS Biotech's significant backing from leading investors, including Avego and BroadOak, underscores the company's position as a key player in the biotechnology landscape. The company focuses on manufacturing single-use bioreactor systems while providing robust process development services that cater to a broad spectrum of cell therapy and culture applications.

As the demand for allogeneic cell-based therapies continues to surge, PBS Biotech is determined to establish its Vertical-Wheel® technology as the global standard manufacturing platform. This ambition illustrates the company’s commitment not only to innovation but also to enhancing the overall efficacy and efficiency of cell therapy development.

For more information on PBS Biotech and its breakthrough products, visit pbsbiotech.com.